Dcspka, William Gartner's plan in 2010/2011 was to merge Provista Life Sciences with Radient. That all fell through when Radient fell on its sword and Gartner went to plan B and sold the licenses of the breast and ovarian cancer markers to a new company called Provista diagnostics.
After Provista Diagnostics was created, a group of new investors wanted different management and dumped Gartner. Gartner was then no longer interested in a merger with a defunct Radient and made the deal to get all the know how for his LC Sentinel / The lung Cancer Test and license from Radient.
At this point, there would be no need or interest in a merger with Radient where he would take on more than 20 million in debt.
Any wild theories that Radient has any value remaining for any type of deal is just hogwash. In just over a month, there will be no patent left and a license deal for peanuts was made with UNI that will expire in just over a month.
I have never shorted nor intend to have any financial interest in this stock. I am not connected with anyone who trades, shorts or has financial interests in this stock. I only post facts and my opinions. I do not post on IHUB with different aliases.
